Navamedic ASA: Broad launch for Eroxon® in Sweden today
Oslo, 6 May 2024 - Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies has launched Eroxon® in Sweden. Eroxon® is clinically proven and considered a breakthrough in treatment of erectile dysfunction for men and will be the first non-prescription treatment for erectile dysfunction in the Swedish market.
Dela artikeln
Taggar: navamedic, broad, launch
Läs vidare på Dagens IndustriRelaterade nyheter
- Navamedic Q4 and full year 2023: A year marked by new records and transformative growth initiatives
- Navamedic ASA: Renewed contract signed with Vitaflo International Limited
- Navamedic ASA: Record high quarter with above 50 percent growth
- Navamedic ASA: Significant growth across the business
- Navamedic tar hand om folkhälsan och går mot fortsatt tillväxt ⎮ #Investtalks
Fler ekonominyheter
- Navamedic Q4 and full year 2023: A year marked by new records and transformative growth initiatives
- Navamedic ASA: Renewed contract signed with Vitaflo International Limited
- Navamedic ASA: Record high quarter with above 50 percent growth
- Navamedic ASA: Significant growth across the business
- Navamedic tar hand om folkhälsan och går mot fortsatt tillväxt ⎮ #Investtalks